These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 28410406)

  • 1. Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers.
    Kato T; Honda Y; Kurita Y; Iwasaki A; Sato T; Kessoku T; Uchiyama S; Ogawa Y; Ohkubo H; Higurashi T; Yamanaka T; Usuda H; Wada K; Nakajima A
    PLoS One; 2017; 12(4):e0175626. PubMed ID: 28410406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice.
    Arakawa K; Ishigami T; Nakai-Sugiyama M; Chen L; Doi H; Kino T; Minegishi S; Saigoh-Teranaka S; Sasaki-Nakashima R; Hibi K; Kimura K; Tamura K
    PLoS One; 2019; 14(6):e0218096. PubMed ID: 31206525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of Test for "Leaky Gut" Small Intestinal and Colonic Permeability Using Sugars in Healthy Adults.
    Khoshbin K; Khanna L; Maselli D; Atieh J; Breen-Lyles M; Arndt K; Rhoten D; Dyer RB; Singh RJ; Nayar S; Bjerkness S; Harmsen WS; Busciglio I; Camilleri M
    Gastroenterology; 2021 Aug; 161(2):463-475.e13. PubMed ID: 33865841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
    Kessoku T; Imajo K; Kobayashi T; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Saito S; Nakajima A
    Contemp Clin Trials; 2018 Jun; 69():40-47. PubMed ID: 29627620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the capability of a gelling complex made of tara gum and the exopolysaccharides produced by the microorganism Streptococcus thermophilus ST10 to prospectively restore the gut physiological barrier: a pilot study.
    Del Piano M; Balzarini M; Carmagnola S; Pagliarulo M; Tari R; Nicola S; Deidda F; Pane M
    J Clin Gastroenterol; 2014; 48 Suppl 1():S56-61. PubMed ID: 25291130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype.
    Solem CT; Patel H; Mehta S; Mody R; Macahilig C; Gao X
    Curr Med Res Opin; 2016 May; 32(5):899-905. PubMed ID: 26836030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
    Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
    J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients.
    Christie J; Shroff S; Shahnavaz N; Carter LA; Harrison MS; Dietz-Lindo KA; Hanfelt J; Srinivasan S
    Am J Gastroenterol; 2017 Feb; 112(2):356-364. PubMed ID: 27922028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation.
    Sarosiek I; Bashashati M; Alvarez A; Hall M; Shankar N; Gomez Y; McCallum RW; Sarosiek J
    Am J Med Sci; 2016 Sep; 352(3):231-8. PubMed ID: 27650225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone.
    Kang DW; DiBaise JK; Ilhan ZE; Crowell MD; Rideout JR; Caporaso JG; Rittmann BE; Krajmalnik-Brown R
    Anaerobe; 2015 Jun; 33():33-41. PubMed ID: 25617726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR-based urinary profiling of lactulose/mannitol ratio used to assess the altered intestinal permeability in acute on chronic liver failure (ACLF) patients.
    Kumar D; Pandey G; Bansal D; Rawat A; Kumar U; Dubey D; Guleria A; Saraswat VA
    Magn Reson Chem; 2017 Apr; 55(4):289-296. PubMed ID: 27623987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic stress and intestinal permeability: Lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human.
    Zong Y; Zhu S; Zhang S; Zheng G; Wiley JW; Hong S
    Neurogastroenterol Motil; 2019 Feb; 31(2):e13477. PubMed ID: 30284340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lubiprostone for Opioid-Induced Constipation Does Not Interfere with Opioid Analgesia in Patients with Chronic Noncancer Pain.
    Spierings EL; Brewer RP; Rauck RL; Losch-Beridon T; Mareya SM
    Pain Pract; 2017 Mar; 17(3):312-319. PubMed ID: 26990171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li F; Fu T; Tong WD; Liu BH; Li CX; Gao Y; Wu JS; Wang XF; Zhang AP
    Mayo Clin Proc; 2016 Apr; 91(4):456-68. PubMed ID: 27046523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lubiprostone: RU 0211, SPI 0211.
    Drugs R D; 2005; 6(4):245-8. PubMed ID: 15991886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary excretion of gluten immunoreactive peptides as an indicator of gastrointestinal function after fasting and dietary provocation in healthy volunteers.
    Rodríguez-Ramírez R; Fernández Peralbo MA; Mendía I; Long JCD; Sousa C; Cebolla Á
    Front Immunol; 2024; 15():1433304. PubMed ID: 39161759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.
    Iturrino J; Camilleri M; Acosta A; O'Neill J; Burton D; Edakkanambeth Varayil J; Carlson PJ; Zinsmeister AR; Hurt R
    JPEN J Parenter Enteral Nutr; 2016 Nov; 40(8):1089-1095. PubMed ID: 26223941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of intestinal permeability using sugar probes: influence of urinary volume.
    Mattioli F; Fucile C; Marini V; Isola L; Montanaro F; Savarino V; Martelli A
    Clin Lab; 2011; 57(11-12):909-18. PubMed ID: 22239021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short Chain Fatty Acids Effect on Chloride Channel ClC-2 as a Possible Mechanism for Lubiprostone Intestinal Action.
    Catalán MA; Julio-Kalajzić F; Niemeyer MI; Cid LP; Sepúlveda FV
    Cells; 2020 Jul; 9(8):. PubMed ID: 32722648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.
    Chang L; Chey WD; Drossman D; Losch-Beridon T; Wang M; Lichtlen P; Mareya S
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1114-1122. PubMed ID: 27669680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.